Loading...
PolarityTE, Inc.
PTE•NASDAQ
Healthcare
Biotechnology
$0.24
$-0.00(-0.82%)

Financial performance has remained strong, with revenue growing from $73000.00 in Q2 2022 to $0.00 in Q1 2023. Gross profit continued to perform well, with margins at N/A in the latest quarter. Operating income reached -$4.80M in Q1 2023, holding a steady N/A margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$5.07M. Net income dropped to -$3.24M, keeping EPS at -$0.44. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan